Clinical Trial Results:
Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale
Summary
|
|
EudraCT number |
2010-024428-10 |
Trial protocol |
FR |
Global end of trial date |
06 Aug 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Jun 2022
|
First version publication date |
29 Jun 2022
|
Other versions |
|
Summary report(s) |
end study Publication |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
10-PP-19
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
chu de nice
|
||
Sponsor organisation address |
DRCI-Hôpital de Cimiez - 4 avenue reine victoria, Nice, France, 06003
|
||
Public contact |
Directeur de la Recherche clinique, CHU de nice - DRCI, +33 492034011, caillon.c@chu-nice.fr
|
||
Scientific contact |
Investigateur Principal, CHU de Nice - DR Chiaverini, +33 492036488, chiaverini.c@chu-nice.fr
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
06 Aug 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
06 Aug 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Aug 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective is to estimate the efficiency of the oral érythromycine to decrease the number of cutaneous bubbles at the patients affected by EBS-DM after 3 months of treatment.
|
||
Protection of trial subjects |
Patients of both sexes, aged 1–8 years who had EBS-gen-sev with at least two new blisters per day were eligible for the study. The parents signed the consent for the clidrens'participation.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
29 Jun 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
France: 5
|
||
Worldwide total number of subjects |
5
|
||
EEA total number of subjects |
5
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
5
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
- | ||||||
Pre-assignment
|
|||||||
Screening details |
At baseline, after 1 month and 3 months of treatment, the patients were seen for body examination, questionnaire, photographs, blood tests and bacteriological swabs. Itch severity and skin fragility were evaluated by parents on a visual analogue scale. At 5 months, we asked all parents for their opinion regarding the tolerability and efficacy | ||||||
Period 1
|
|||||||
Period 1 title |
Inclusion Period (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Oral erythromycin therapy | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
erythromycin
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Syrup
|
||||||
Routes of administration |
Buccal use
|
||||||
Dosage and administration details |
. A weight-based dosage was calculated for the children (< 10 kg, 250 mg per day; 10–15 kg, 500 mg per day; 15–25 kg, 750 mg per day; 25–35 kg, 1000 mg per
day).
|
||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Oral erythromycin therapy
|
||
Reporting group description |
- |
|
|||||||
End point title |
The efficacy of treatment evaluate by parents [1] | ||||||
End point description |
|||||||
End point type |
Primary
|
||||||
End point timeframe |
At baseline, after 1 month and 3 months of treatment
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The description is in the arcticle |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
At baseline, after 1 month and 3 months of treatment
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
17
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: There is no adverse serious event |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
07 Jul 2011 |
Increase in upper age limit |
||
07 Jul 2011 |
modification of the route of administration of the medicinal product |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |